GENOMIC HEALTH,INC. (NASDAQ:GHDX) Files An 8-K Results of Operations and Financial Condition

GENOMIC HEALTH,INC. (NASDAQ:GHDX) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

Story continues below

On February 14, 2017, Genomic Health, Inc. issued a press release announcing financial results for its fourth fiscal quarter and year ended December 31, 2016. The full text of the press release is furnished as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press release issued by Genomic Health, Inc. dated February 14, 2017.


About GENOMIC HEALTH, INC. (NASDAQ:GHDX)

Genomic Health, Inc. is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer. Its Oncotype DX tests utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. It offers its services and products, including Oncotype DX Breast Cancer Test, Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test through its Oncotype IQ Genomic Intelligence Platform.

GENOMIC HEALTH, INC. (NASDAQ:GHDX) Recent Trading Information

GENOMIC HEALTH, INC. (NASDAQ:GHDX) closed its last trading session up +0.26 at 28.23 with 109,635 shares trading hands.

An ad to help with our costs